These stocks are proven winners in December

December is historically a strong month for equities (third-best month for the Dow and S&P since 1950 and the Nasdaq since 1971), and a handful of stocks have delivered outsized December returns over the past decade. Broadcom has rallied ~72% YTD and averaged >10% gains in December while sitting on a 3.5% upside to the consensus price target and a consensus buy rating after Goldman Sachs lifted its target citing momentum into the next earnings report. Estee Lauder averages a 4.6% December gain and shows ~10% upside to the average price target despite only 32% of analysts rating it a buy. Eli Lilly, which recently reached a $1 trillion market cap, has averaged a 4.3% December advance but is forecast to be ~1.5% below its consensus price target.

Analysis

Market structure: December seasonality and momentum disproportionately benefit large-cap, low-float winners — Broadcom (AVGO) is the clearest beneficiary given YTD +72% and a 10-year average December lift ~+10%. That concentrates active flows into semis/software names and into index-heavy long-only funds, compressing implied volatility and enabling short-premium strategies; downside is crowding risk if a single earnings miss triggers rapid outflows.

Risk assessment: Tail risks include an earnings-guidance miss at AVGO (operational) or renewed regulatory scrutiny into semiconductor M&A/licensing (regulatory) that could swing price 15–30% fast. Timeline: immediate (days) — window dressing and analyst upgrades can add 3–8% moves; short-term (weeks) — quarterly earnings and December rebalancings; long-term (12–24 months) — secular AI/telecom capex supports demand but depends on customer spend elasticity and channel inventory.

Trade implications: Direct play = tactically long AVGO into December with defined risk (see decisions). Use call spreads to cap premium given compressed IV; consider selling short-dated calls post-entry. For healthcare (LLY) and discretionary (EL), prioritize hedges or option-driven exposure: LLY has less upside vs price target and is a candidate for profit-taking or protective puts.

Contrarian angles: Consensus leans bullish on seasonality; what’s missing is positioning concentration and IV complacency — the market may underprice a 10–20% mean reversion during a macro shock. Historical parallel: crowded December rallies often reverse in January when flows revert, so prefer option-defined risk and pair trades rather than naked long exposure.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in AVGO by Dec 3 to capture seasonal upside (historical +~10%); set a hard stop at -10% and a staged take-profit: trim 50% at +10% and the remainder at +20% or on any guidance cut.
• Implement a defined-risk options trade on AVGO instead of naked stock: buy a Dec monthly call spread (buy ATM, sell 10–12% OTM) sized at 0.5–1% portfolio risk to capture the consensus +3.5% to +10% upside while limiting premium spend; close on expiry or if spread hits 70% of max profit.
• Trim 20–30% of any Eli Lilly (LLY) exposure or buy short-dated protective puts equal to 1–2% portfolio risk (8–12% downside protection band) ahead of year-end given limited upside to consensus target and concentrated positioning risk.
• Take a small contrarian pair: go long AVGO (1.5% portfolio) and short SPY equal-dollar (1.5%) for 4–6 weeks to isolate AVGO idiosyncratic upside vs market beta; unwind by Jan 10 or on SPY outperformance >5% or AVGO underperformance >8%.